Latest Raloxifene Stories
Today's major announcement at the American Society of Clinical Oncology annual meeting that the drug exemestane significantly reduces the risk of breast cancer in high-risk, postmenopausal women is the result of an international, randomized double-blind phase III clinical trial in which University at Buffalo researchers and hundreds of Western New York women played a critical role.
BALTIMORE, May 6, 2011 /PRNewswire/ -- Stenting is safe and effective and superior to balloon angioplasty for treatment of venous stenosis in patients with deep vein thrombosis (DVT), according to results from EVISTA-DVT, presented today as a Late-Breaking Clinical Trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2011 Scientific Sessions in Baltimore.
Recent research indicates medications such as Tamoxifen or Raloxifene considerably reduce the risk of developing breast cancer in post-menopausal women.
ROCKVILLE, Md., Jan. 17, 2011 /PRNewswire-USNewswire/ -- In an update to its 2002 recommendation, the U.S. Preventive Services Task Force (USPSTF) now recommends that all women ages 65 and older be routinely screened for osteoporosis.
Results from an ongoing study examining two drugs to prevent breast cancer found that the drug raloxifene (Evista) was as almost effective as the standard drug tamoxifen (Nolvadex) and also produced fewer side effects.
EMERYVILLE, Calif., Dec. 8, 2010 /PRNewswire/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced the publication of a study demonstrating that ERb causes cancer cell growth arrest by inactivating critical genes and enzymes responsible for cell growth.
Lasofoxifene statistically reduced the overall risk of breast cancer, as well as ER positive invasive breast cancer in postmenopausal women with low bone density.
INDIANAPOLIS, Oct. 14 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) today announced that a total of 14 U.S.
BURLINGTON, Mass., Sept.